目的：探讨自微乳化给药系统(SMEDDS)促进银杏酮酯(GBE50)口服吸收的效果。方法采用高效液相色谱法,以其市售颗粒剂做对照,桑色素为内标,柚皮素、黄芩素、槲皮素为对照品,进行大鼠体内生物利用度研究,并利用DAS药动学软件处理血药浓度数据。结果血药浓度数据表明,市售的对照品颗粒剂与银杏酮酯口服自微乳化给药系统(GBE50-SMEDDS)对比,发现对照品颗粒剂消除半衰期(t1/2β)、药峰浓度(Cmax)和0~25 h药时曲线下面积(AUC0-25)分别为(4.327±0.768)h,(199.49±24.59) ng/ml,(240.29±24.22)mg/(h·ml) GBE50-SMEDDS则分别为(10.975±1.887)h,(221.53±46.88)ng/ml,(378.83±20.65)mg/(h·ml),两组t1/2β、Cmax和AUC0-25比较,差异有统计学意义(P<0.05)。结论与市售颗粒剂相比, GBE50-SMEDDS明显提高了生物利用度,在临床上值得推广应用。%Objective To investigate the self-microemulsifying drug delivery system(SMEDDS)for promoting oral bioavailability. Methods Chose commercially available granule as a comparison, morin as a internal standard, and naringenin, baicalein and quercetin as reference substance for bioavailability studies in mice by high performance liquid chromatography(HPLC), used DAS pharmaco-kinetics software to process blood drug concentration data. Results The t1/2β, Cmax and AUC0-25 of commercially available granule were (4.327±0.768)h, (199.49±24.59)ng/ml, (240.29±24.22)mg/(h·ml) and GBE50-SMEDDS were (10.975±1.887) h, (221.53±46.88)ng/ml, (378.83±20.65)mg/(h·ml), t1/2β, Cmax and AUC0-25 of two groups were statistically significant. Conclusion The Ginkgo biloba extract 50(GBE50) which based on SMEDDS have higher bioavai-lability than the present commercially available granule, so it is worthy of clinical promotion.
展开▼
